46 research outputs found
Signal transduction in apoptosis induced by anticancer agents.
No full textSignal transduction in apoptosis induced by anticancer agents
MineDojo Internet Knowledge Base (Wiki)
No full textProject website: minedojo.org
Paper: arxiv.org/abs/2206.08853
GitHub: github.com/MineDojo/MineDojo
The Minecraft Wiki pages cover almost every aspect of the game mechanics, and supply a rich source of unstructured knowledge in multimodal tables, recipes, illustrations, and step-by-step tutorials. We scrape 6,735 pages that interleave text, images, tables, and diagrams. To preserve the layout information, we also save the screenshots of entire pages and extract bounding boxes of the visual elements.
There are two files in our Wiki knowledge base.
wiki_samples.zip: A sample version of the full knowledge base (10 pages).
wiki_full.zip: The full knowledge base (6,735 pages).
Cite Us
@article{fan2022minedojo,
title = {MineDojo: Building Open-Ended Embodied Agents with Internet-Scale Knowledge},
author = {Linxi Fan and Guanzhi Wang and Yunfan Jiang and Ajay Mandlekar and Yuncong Yang and Haoyi Zhu and Andrew Tang and De-An Huang and Yuke Zhu and Anima Anandkumar},
year = {2022},
journal = {arXiv preprint arXiv: Arxiv-2206.08853}
MineDojo Internet Knowledge Base (Reddit)
No full textProject website: minedojo.org
Paper: arxiv.org/abs/2206.08853
GitHub: github.com/MineDojo/MineDojo
We collect 340K+ Reddit posts along with 6.6M comments under the “r/Minecraft” subreddit. These posts ask questions on how to solve certain tasks, showcase cool architectures and achievements in image/video snippets, and discuss general tips and tricks for players of all expertise levels. Large language models can be finetuned on our Reddit corpus to internalize Minecraft-specific concepts and develop sophisticated strategies.
Cite Us
@article{fan2022minedojo,
title = {MineDojo: Building Open-Ended Embodied Agents with Internet-Scale Knowledge},
author = {Linxi Fan and Guanzhi Wang and Yunfan Jiang and Ajay Mandlekar and Yuncong Yang and Haoyi Zhu and Andrew Tang and De-An Huang and Yuke Zhu and Anima Anandkumar},
year = {2022},
journal = {arXiv preprint arXiv: Arxiv-2206.08853}
Spotting of external calibration standards on blank dried blood spots as a resource-sparing protocol
No full text Aim: Dried blood spots (DBS) offer significant ethical and scientific advantages; however preparation of calibration curves often times, off-sets some of these advantages. We have developed a methodology wherein small volumes of external calibration standards can be spiked on to blank DBS cards. Results: A total of 2 μl of stock solution spotted on to blank blood spots yielded concentrations that were comparable to those obtained using conventional DBS method. The stability of six analytes on 10-day-old blank spots was within 80–120%. The new methodology was successfully applied to a hydroxycholorquine mouse pharmacokinetics study. Conclusion: Blank DBS samples can be opportunistically prepared from overweight or satellite animals, be stored, and subsequently spiked with standards to prepare calibration standards. </jats:p
LC–MS determination of triazolam and its hydroxy metabolites in mouse dried blood spots: application to transgenic mouse pharmacokinetic studies
No full text Aim: The objective of this study was to develop a LC–MS/MS method for the simultaneous determination of triazolam (TRZ) and its two hydroxy metabolites in transgenic mouse dried blood spots (DBS) using BALB/c mouse blood as a surrogate biomatrix. Methodology/Results: The DBS method involved spotting volume of 10 μl using Ahlstrom 226 sample collection cards. A ‘whole spot’ analysis (6-mm punch) involved extraction of analytes using water and acetonitrile containing an internal standard. DBS samples were analyzed by a validated LC–MS/MS method with a run time of 4 min. Conclusion: This validated LC–MS/MS method using DBS extraction was applied to quantitation of TRZ, α-hydroxytriazolam and 4-hydroxytriazolam in a CYP3A4 transgenic mouse oral pharmacokinetic study of TRZ. </jats:p
Molecular Mechanisms of Butylated Hydroxylanisole-Induced Toxicity: Induction of Apoptosis through Direct Release of Cytochrome<i>c</i>
No full textAbstract CT029: Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation
No full textBackground: GDC-6036 is an oral, highly potent and selective KRAS G12C inhibitor that demonstrated anti-tumor activity in patients with KRAS G12C-positive advanced solid tumors, including CRC. In a previously reported single-agent cohort, GDC-6036 achieved a best response of partial response or complete response in 35% (19/55) of patients, with a confirmed overall response rate (ORR) of 24% (13/55 patients) in KRAS G12C-positive CRC patients (Desai et. al., ESMO 2022). EGFR blockade may sensitize tumors to KRAS G12C inhibition and the combination of an anti-EGFR antibody (cetuximab) with a KRAS G12C inhibitor showed greater anti-tumor activity than single-agent KRAS G12C inhibition in preclinical models (Amodio et. al., 2020). Methods: In an ongoing Phase I study (NCT04449874), patients with advanced or metastatic KRAS G12C-positive CRC were administered GDC-6036 (200-400 mg orally once a day) with cetuximab (400 mg/m2 intravenously initially, then 250 mg/m2 weekly) until intolerable toxicity or disease progression. Endpoints included safety (NCI-CTCAE v5), pharmacokinetics (PK), and preliminary anti-tumor activity (RECIST v1.1). Results: As of the clinical data cut-off date of 21 Nov 2022, 29 patients (enrolled by 07 Oct 2022) had received GDC-6036 and cetuximab. The median lines of prior metastatic therapy was 2 (range 1-8) and the median time on study treatment was 5.2 (range 1.4-11.2) months. All patients experienced at least one treatment-related adverse event (TRAE); the most common TRAEs (≥15%) were rash (grouped terms), diarrhea, nausea, vomiting, dry skin, and paronychia. Grade 3-4 TRAEs occurred in 11 patients (38%). Five patients (17%) experienced at least one serious AE, none of which were treatment-related (including 2 patients who died of CRC progression during the safety follow-up). AEs led to GDC-6036 modifications (interruptions and/or reductions) in 13 (45%) patients, dose reduction in 3 (10%) patients, and no patients discontinued due to AEs. Eleven patients discontinued from study treatment (10 due to disease progression and 1 due to physician’s discretion). The PK profile of GDC-6036 (400 mg once a day) was similar in combination with cetuximab when compared with single-agent. A partial response was achieved in 66% (19/29) of patients, with a confirmed ORR of 62% (18/29 patients). Conclusions: GDC-6036 in combination with cetuximab demonstrated a manageable safety profile and promising clinical activity. These data support that the addition of anti-EGFR therapy to GDC-6036 may lead to robust clinical benefit in patients with KRAS G12C-positive CRC.Citation Format: Jayesh Desai, Sae-Won Han, Jong-Seok Lee, Einat Shacham-Shmueli, Erminia Massarelli, Andrés Cervantes, Elena Garralda, Alejandro Falcon, Wilson H. Miller, Eelke Gort, Thomas Karasic, Salvatore Siena, Rafal Stec, Laura Medina, Luis Paz-Arez, Angelo Delmonte, Adrian Sacher, Hans Prenen, Martin Forster, Tae Won Kim, Matthew G. Krebs, Rasha Cosman, Yoonha Choi, Sandhya Mandlekar, Mark T. Lin, Kenneth K. Yau, Julie Chang, Stephanie Royer-Joo, Neekesh V. Dharia, Jennifer L. Schutzman, Manish Patel. Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT029
Activation of p38 and c-Jun N-terminal Kinase Pathways and Induction of Apoptosis by Chelerythrine Do Not Require Inhibition of Protein Kinase C
No full text
